Dr. De Golia specializes in the treatment of mood and anxiety disorders with an expertise in time-limited dynamic psychotherapy. She is Section Chief of the Assessment Clinics and Director of the Evaluation Clinic. Dr. De Golia is the Associate Chair for Clinician Educator Professional Development where she is involved in developing faculty development programs including mentorship. She is also the Associate Residency Director of the Adult Psychiatry Residency Program where she has been involved in educational programming and curricular development. She is a Peer Teaching Coach in the Stanford Teaching and Mentoring Academy, teaches regularly with the Stanford Center for Faculty Development, and is a Senior Fellow at Stanford's Center for Innovation in Global Health. She currently serves on the Executive Committee of the American Association of Directors of Psychiatry Residency Training.

Clinical Focus

  • Psychiatry
  • Psychotherapy and psychopharmacology, Time-limited Dynamic Psychotherapy, Women's issues.

Academic Appointments

  • Clinical Professor, Psychiatry and Behavioral Sciences

Administrative Appointments

  • Associate Chair Clinician Educator Line, Stanford Department of Psychiatry and Behavioral Sciences (2016 - Present)
  • Senior Fellow, Center for Innovation in Global Health (2015 - Present)
  • Associate Residency Director, Department of Psychiatry and Behavioral Sciences (2007 - Present)

Honors & Awards

  • Irma Bland Award for Residency Education Excellence., American Psychiatric Association (2015)
  • Most Inspiring Mentor, Stanford Adult Psychiatry Residency (2015)
  • Education Mission Award, Stanford Department of Psychiatry and Behavioral Sciences (2014)
  • Teacher's Award, American Psychoanalytic and Psychodynamic Association (2014)

Boards, Advisory Committees, Professional Organizations

  • Co-Chair Membership Committee, American Association of Directors of Psychiatry Residency Training (2014 - Present)

Professional Education

  • Internship:Santa Clara Valley Medical Center Radiology Residency (1993) CA
  • Residency:Stanford University School of Medicine Registrar (1996) CA
  • Medical Education:Stanford University School of Medicine (1992) CA
  • MPH, Columbia University School of Public Health, Maternal & Child Health (1986)
  • Board Certification: Psychiatry, American Board of Psychiatry and Neurology (2000)

Research & Scholarship


  • Flipped Classroom/Team-based Learning Project., Stanford University (3/1/2013)

    Development of a flipped classroom combined with Team Based Learning methods within a previously, traditionally taught PGY II Psychopharm/psychopathology 9-month course in the Department of Psychiatry. VPOL funded.


    Department of Psychiatry and Behavioral Sciences, Stanford, CA

  • Medical Student Reflection Group Study, Stanford Medical School (2/1/2017 - 6/30/2018)

    Resident-run bi-weekly reflection groups for Stanford Medical Students


    Stanford, CA


    • Jessica Gold, Psychiatry and Behavioral Sciences
    • Craig Forte, Psychiatry and Behavioral Sciences
    • Jessica Bentzley, School of Medicine - Dean's Office


2018-19 Courses


All Publications

  • Early Outpatient Experience for Psychiatry Interns: The Evaluation Clinic Academic Psychiatry Gold, J., Bandstra, B., DeGolia, S. 2016: 944–46
  • Developing a Mental Health Curriculum to Build Capacity and Improve Access to Mental Health Care in Rural Guatemala Academic Psychiatry Rissman, Y., Isaac, S., Khan, C., DeGolia, S. 2016
  • Limits to Scholarship: How Can We Enhance the Program Director's Role? Academic psychiatry De Golia, S. G., Katznelson, L. 2015; 39 (1): 70-72

    View details for DOI 10.1007/s40596-014-0255-z

    View details for PubMedID 25467936

  • Job Satisfaction Among Associate Training Directors in Psychiatry: A Bimodal Distribution ACADEMIC PSYCHIATRY Arbuckle, M. R., DeGolia, S. G., Esposito, K., Weinberg, M., Brenner, A. M. 2013; 37 (2): 129-130

    View details for Web of Science ID 000316155900017

    View details for PubMedID 23475249

  • How to give an Effective Lecture Achievement and Fulfillment in Academic Medicine: A Comprehensive Guide DeGolia, S. edited by Roberts, L. Springer. 2013; 1st
  • Associate Residency Training Directors in Psychiatry: Demographics, Professional Activities, and Job Satisfaction ACADEMIC PSYCHIATRY Arbuckle, M. R., DeGolia, S. G., Esposito, K., Miller, D. A., Weinberg, M., Brenner, A. M. 2012; 36 (5): 391-394


    The purpose of this study was to characterize associate training director (ATD) positions in psychiatry.An on-line survey was e-mailed in 2009 to all ATDs identified through the American Association of Directors of Psychiatric Residency Training (AADPRT). Survey questions elicited information regarding demographics, professional activities, job satisfaction, and goals.Of 170 ATDs surveyed, 73 (42.9%) completed the survey. Most respondents (71.3%) had been in their positions for 3 years or less. Many ATDs indicated that they were involved in virtually all aspects of residency training; 75% of respondents agreed that they were happy with their experience. However, specific concerns included inadequate time and compensation for the ATD role in addition to a lack of mentorship and unclear job expectations.Thoughtful attention to the construction of the ATD role may improve job satisfaction.

    View details for Web of Science ID 000308454500010

    View details for PubMedID 22983471

  • Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression JOURNAL OF AFFECTIVE DISORDERS Winsberg, M. E., DeGolia, S. G., Strong, C. M., Ketter, T. A. 2001; 67 (1-3): 207-212


    There have been few systematic studies of the treatment of bipolar II depression. While divalproex sodium (DVPX) is effective in acute mania, there are few data on the antidepressant effects of DVPX. Similarly, little is known regarding the use of DVPX administered in a single daily dose.We performed a 12-week open trial of DVPX monotherapy (mean dose 882 mg qhs, mean level 80.7 mug/ml) in nineteen (thirteen women, six men, mean age 29) bipolar II depressed outpatients. Eleven patients (six women, five men) were medication-naive (MN) and eight (seven women, one man) were mood stabilizer-naive (MSN), having had prior trials of antidepressants or stimulants. Mean illness and current depressive episode duration were 15.4 years and 11.8 weeks, respectively. DVPX was given as a single dose each evening starting with 250 mg at bedtime and increased by 250 mg at bedtime every 4 days until symptom relief or adverse effects were noted. Weekly prospective Hamilton Depression, Young Mania and Clinical Global Impression ratings were obtained.DVPX therapy was generally well tolerated. Twelve of nineteen patients (63%) responded (>50% decrease in Hamilton Depression ratings). MN patients compared to MSN patients tended to have a higher response rate (9/11 versus 3/8, P<0.08). Mean Hamilton scores decreased from 22.2 to 9.6 (P<0.0001) in the entire group, from 20.6 to 6.6 (P<0.0003) in MN patients, and from 24.2 to 14.7 (P=0.008) in MSN patients.Single daily dose DVPX monotherapy appeared to be well tolerated and substantially benefited 63% of patients with bipolar II depression. The trend towards a higher rate of antidepressant response to DVPX in MN patients (82%) compared to MSN patients (38%) could be due to a milder form or earlier phase of illness and the lack of prior medication exposure or failures. This uncontrolled open pilot study must be viewed with caution, and randomized double-blind placebo controlled studies of DVPX in bipolar II depression are warranted to confirm the possibility that single daily dose DVPX is an effective, well-tolerated, first-line monotherapy in this population.

    View details for Web of Science ID 000174633800023

    View details for PubMedID 11869770

  • Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states JOURNAL OF CLINICAL PSYCHIATRY Ketter, T. A., Winsberg, M. E., DeGolia, S. G., Dunai, M., Tate, D. L., Strong, C. M. 1998; 59 (2): 83-85

    View details for Web of Science ID 000072288800011

    View details for PubMedID 9501894